Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)
Published in: Irish Journal of Medical Science (1971 -) 1/2020

01-02-2020 | Mood Disorders | Original Article

May zoledronic acid have negative effects on cognition and muscle performance?

Authors: Remzi Bahşi, Volkan Atmiş, Tuğba Turgut, Deniz Mut Sürmeli, Çağlar Coşarderelioğlu, Hande Selvi Öztorun, Ahmet Yalçin, Sevgi Aras, Murat Varli

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2020

Login to get access

Abstract

Background

We aimed to investigate the effects of zoledronic acid treatment on daily living activities, cognitive functions, depression, muscle strength, and performance.

Methods

The study was conducted retrospectively. Bone mineral densitometry (BMD) values, Katz activities of daily living (ADL), Lawton-Brody instrumental activities of daily living (IADL), mini mental state examination (MMSE), geriatric depression scale (GDS), mini nutritional assessment (MNA), grip strength, and gait speed scores before and 6 months after zoledronic acid administration were compared.

Results

A total of 115 patients were included in the study. There was a significant increase in lumbar total (p < .001), femoral neck (p = .002), and femur total (p = .001) BMD values after zoledronic acid treatment. Significant decrease was found in MMSE (p = .016) and gait speed scores (p = .008) after zoledronic acid treatment, but no significant difference was found in terms of Katz ADL, Lawton-Brody IADL, MNA, GDS, and grip strength (p > .05).

Conclusion

Our study indicated that zoledronic acid did not affect daily living activities, depression, and muscle strength. Although we have concluded that cognitive and muscle performance may be adversely affected by zoledronic acid treatment.
Literature
1.
2.
Maclaughlin EJ, Sleeper RB, McNatty D et al (2006) Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2(3):281–295PubMedPubMedCentralCrossRef
3.
Zadeh AF, Hanafi MG, Kiasat A, Mousavi M (2019) Evaluation of the tibial cortical thickness accuracy in osteoporosis diagnosis in comparison with dual energy X-ray absorptiometry. J Family Med Prim Care 8(2):523–527PubMedPubMedCentralCrossRef
4.
U.S. Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356–364CrossRef
5.
6.
7.
Pazianas M, Abrahamsen B, Ferrari S, Russell RG (2013) Eliminating the need for fasting with oral administration of bisphosphonates. Ther Clin Risk Manag 9:395–402PubMedPubMedCentralCrossRef
8.
Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT (2010) Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosismanagement. Drug Healthc Patient Saf 2:121–137PubMedPubMedCentralCrossRef
9.
Dilek B, Şahin E, Erdem D, et al. (2017) Patient satisfaction, preference and side effects after annual zoledronic acid infusion in patients with osteoporosis 23(1): 21–25
10.
Liu M, Guo L, Pei Y, Li N, Jin M, Ma L, Liu Y, Sun B, Li C (2015) Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis. Int J Clin Exp Med 8(3):3855–3861PubMedPubMedCentral
11.
Wang C (2017) Efficacy and safety of zoledronic acid for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Am J Ther 24(5):e544–e552PubMedCrossRef
12.
Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18(9):1211–1218PubMedCrossRef
13.
Hsieh PC (2016) Effectiveness and safety of zoledronic acid in the treatment of osteoporosis. Orthopedics. 39(2):e263–e270PubMedCrossRef
14.
Kotian P, Boloor A, Sreenivasan S (2016) Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis. J Clin Diagn Res 10(1):OC04–OC06PubMedPubMedCentral
15.
Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J, Mesenbrink P, de Villiers TJ (2012) Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 23(2):503–512PubMedCrossRef
16.
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809PubMedCrossRef
17.
Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367(18):1714–1723PubMedCrossRef
18.
Tasci I, Safer U, Cintosun U, Bozoglu E, Naharci I, Aydogdu A, Meric C, Doruk H (2016) Zoledronic acid use and risk of cognitive decline among elderly women and men with osteoporosis. Endocr Metab Immune Disord Drug Targets 16(1):32–38PubMedCrossRef
19.
Gokosmanoglu F, Varim C, Atmaca A et al (2016) The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: a clinical trial study. J Res Med Sci 21:112PubMedPubMedCentralCrossRef
20.
Arik G, Varan HD, Yavuz BB, Karabulut E, Kara O, Kilic MK, Kizilarslanoglu MC, Sumer F, Kuyumcu ME, Yesil Y, Halil M, Cankurtaran M (2015) Validation of Katz index of independence in activities of daily living in Turkish older adults. Arch Gerontol Geriatr 61(3):344–350PubMedCrossRef
21.
Hopkins RO, Suchyta MR, Kamdar BB, Darowski E, Jackson JC, Needham DM (2017) Instrumental activities of daily living after critical illness: a systematic review. Ann Am Thorac Soc 14(8):1332–1343PubMedPubMedCentralCrossRef
22.
Goudsmit M, van Campen J, Schilt T, Hinnen C, Franzen S, Schmand B (2018) One size does not fit all: comparative diagnostic accuracy of the rowland universal dementia assessment scale and the mini mental state examination in a memory clinic population with very low education. Dement Geriatr Cogn Dis Extra 8(2):290–305PubMedPubMedCentralCrossRef
23.
Durmaz B, Soysal P, Ellidokuz H, Isik AT (2018) Validity and reliability of geriatric depression scale-15 (short form) in Turkish older adults. North Clin Istanb 5(3):216–220PubMedPubMedCentral
24.
Sarikaya D, Halil M, Kuyumcu ME, Kilic MK, Yesil Y, Kara O, Ozturk S, Gungor E, Karabulut E, Balam Yavuz B, Cankurtaran M, Ariogul S (2015) Mini nutritional assessment test long and short form are valid screening tools in Turkish older adults. Arch Gerontol Geriatr 61(1):56–60PubMedCrossRef
25.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, Bautmans I, Baeyens JP, Cesari M, Cherubini A, Kanis J, Maggio M, Martin F, Michel JP, Pitkala K, Reginster JY, Rizzoli R, Sánchez-Rodríguez D, Schols J (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31PubMedCrossRef
26.
Satoh T, Kimura M, Matsumoto K, Tabata KI, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer. 115(15):3468–3474PubMedCrossRef
27.
Sunyecz JA (2010) Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Women's Health 2:353–360CrossRef
28.
Nasiruddin M, Fayazuddin M, Zahid M et al (2014) Acute delirium in an elderly woman following zoledronate administration. J Pharmacol Pharmacother 5(3):217–219PubMedPubMedCentralCrossRef
29.
Safer U, Safer VB, Demir SO et al (2016) Effects of bisphosphonates and calcium plus vitamin-D supplements on cognitive function in postmenopausal osteoporosis§. Endocr Metab Immune Disord Drug Targets 16(1):56–60PubMedCrossRef
30.
Tow A, Holtzer R, Wang C, Sharan A, Kim SJ, Gladstein A, Blum Y, Verghese J (2016) Cognitive reserve and postoperative delirium in older adults. J Am Geriatr Soc 64(6):1341–1346PubMedPubMedCentralCrossRef
31.
Zameer S, Najmi AK, Vohora D, Akhtar M (2018) Bisphosphonates: future perspective for neurological disorders. Pharmacol Rep 70(5):900–907PubMedCrossRef
32.
33.
Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5PubMedPubMedCentralCrossRef
34.
Metadata
Title
May zoledronic acid have negative effects on cognition and muscle performance?
Authors
Remzi Bahşi
Volkan Atmiş
Tuğba Turgut
Deniz Mut Sürmeli
Çağlar Coşarderelioğlu
Hande Selvi Öztorun
Ahmet Yalçin
Sevgi Aras
Murat Varli
Publication date
01-02-2020
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2020
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-019-02086-5

Other articles of this Issue 1/2020

Irish Journal of Medical Science (1971 -) 1/2020 Go to the issue

Commentary

Hyponatraemia, harm reduction and the O’Hara report from Northern Ireland

Letter to the Editor

Supervised exercise for cardiovascular rehabilitation—the Limerick programme

Original Article

The adequacy of lymph node clearance in colon cancer surgery performed in a non-specialist centre; implications for practice

Original Article

Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis

Review Article

Irish Maternal Early Warning Score

Original Article

AdCom study—adolescent communication group therapy for externalising disorders
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits